The global postmenopausal osteoporosis drugs market is anticipated to grow at a significant CAGR during the forecast period. Postmenopausal osteoporosis is a heterogeneous disorder caused due to progressive loss of bone tissue. It can occur either after natural or surgical menopause and leads to fracture within 15 to 20 years from the cessation of ovarian function. The major factor for the growth of the market is the increasing prevalence of postmenopausal osteoporosis across the globe.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/postmenopausal-osteoporosis-drugs-market
According to the Endocrine Society, approximately 1 in 10 women over the age of 60 are affected by osteoporosis. Additionally, one in two postmenopausal women has osteoporosis while most women suffer a fracture during their lifetime. Hence, the increasing prevalence of postmenopausal osteoporosis is driving the demand for postmenopausal osteoporosis drugs which in turn is driving the growth of the market. Furthermore, the market is growing due to ongoing R&D. For instance, in July 2019, Sandoz (Novartis) announced the first patient enrolled in ROSALIA. It is an integrated Phase I/III clinical study for its proposed biosimilar denosumab. Denosumab is used for the treatment of a variety of conditions such as osteoporosis in postmenopausal women.
Some major players in the market include Eli Lilly and Co., Pfizer, Inc., and Merck & Co., Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2019, Amgen announced the approval of Evenity (romosozumab-aqqg) from the US FDA. It is used for the treatment of osteoporosis in postmenopausal women at high risk of breaking a bone.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Eli Lilly and Co., Pfizer, Inc., and Merck & Co., Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Postmenopausal Osteoporosis Drugs Market Report by Segment
By Type
- Antiresorptive Medications
- Anabolic Medications
By Application
- Hospital
- Pharmacy
- Others
A full report of Postmenopausal Osteoporosis Drugs Market is available at: https://www.omrglobal.com/industry-reports/postmenopausal-osteoporosis-drugs-market
Postmenopausal Osteoporosis Drugs Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Eli Lilly and Co.
- Pfizer, Inc.
- Merck & Co., Inc.
